Brii Biosciences Limited (BRIBF)
OTCMKTS
· Delayed Price · Currency is USD
0.3042
+0.0042 (1.40%)
At close: Mar 31, 2025
Brii Biosciences Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 |
| Operating Revenue | - | 0.62 | 51.63 | - | - | Upgrade
|
| Other Revenue | 54.29 | 55.71 | 70.65 | 92.54 | 82.22 | Upgrade
|
| Revenue | 54.29 | 56.32 | 122.28 | 92.54 | 82.22 | Upgrade
|
| Revenue Growth (YoY) | -3.62% | -53.94% | 32.13% | 12.56% | 307.10% | Upgrade
|
| Gross Profit | 54.29 | 56.32 | 122.28 | 92.54 | 82.22 | Upgrade
|
| Selling, General & Admin | 153.16 | 197.92 | 195.49 | 208.4 | 103.4 | Upgrade
|
| Research & Development | 249.85 | 402.71 | 440.63 | 494.62 | 875.8 | Upgrade
|
| Operating Expenses | 453.79 | 600.62 | 636.12 | 703.02 | 979.19 | Upgrade
|
| Operating Income | -399.5 | -544.3 | -513.85 | -610.48 | -896.97 | Upgrade
|
| Interest Expense | -2.37 | -0.49 | -0.85 | -1.18 | -1.67 | Upgrade
|
| Interest & Investment Income | 87.15 | 108.02 | 37.2 | 6.49 | 2.41 | Upgrade
|
| Currency Exchange Gain (Loss) | - | 121.59 | -43.98 | 0.27 | -6.97 | Upgrade
|
| Other Non Operating Income (Expenses) | -197.67 | - | - | - | - | Upgrade
|
| EBT Excluding Unusual Items | -512.38 | -315.18 | -521.47 | -604.9 | -903.21 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | 136.24 | 31.69 | 44.8 | -15.02 | Upgrade
|
| Asset Writedown | - | -5.43 | - | - | - | Upgrade
|
| Other Unusual Items | - | - | - | -3,631 | -365.28 | Upgrade
|
| Pretax Income | -512.38 | -184.37 | -489.78 | -4,191 | -1,284 | Upgrade
|
| Earnings From Continuing Operations | -512.38 | -184.37 | -489.78 | -4,191 | -1,284 | Upgrade
|
| Minority Interest in Earnings | 4.22 | 9.54 | 5.47 | 27.24 | 93.91 | Upgrade
|
| Net Income | -508.16 | -174.83 | -484.31 | -4,164 | -1,190 | Upgrade
|
| Net Income to Common | -508.16 | -174.83 | -484.31 | -4,164 | -1,190 | Upgrade
|
| Shares Outstanding (Basic) | 730 | 728 | 723 | 439 | 191 | Upgrade
|
| Shares Outstanding (Diluted) | 730 | 728 | 723 | 439 | 191 | Upgrade
|
| Shares Change (YoY) | 0.29% | 0.64% | 64.78% | 129.57% | 7.08% | Upgrade
|
| EPS (Basic) | -0.70 | -0.24 | -0.67 | -9.48 | -6.22 | Upgrade
|
| EPS (Diluted) | -0.70 | -0.24 | -0.67 | -9.48 | -6.22 | Upgrade
|
| Free Cash Flow | - | -594.01 | -496.28 | -880.49 | -403.72 | Upgrade
|
| Free Cash Flow Per Share | - | -0.82 | -0.69 | -2.00 | -2.11 | Upgrade
|
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | Upgrade
|
| Operating Margin | -735.93% | -966.41% | -420.22% | -659.68% | -1090.97% | Upgrade
|
| Profit Margin | -936.08% | -310.41% | -396.07% | -4499.41% | -1446.88% | Upgrade
|
| Free Cash Flow Margin | - | -1054.67% | -405.86% | -951.45% | -491.03% | Upgrade
|
| EBITDA | -392.52 | -537.31 | -505.5 | -602.8 | -890.79 | Upgrade
|
| D&A For EBITDA | 6.99 | 6.99 | 8.35 | 7.68 | 6.19 | Upgrade
|
| EBIT | -399.5 | -544.3 | -513.85 | -610.48 | -896.97 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.